Bigger Regulatory Challenges in Diagnostics Than in Therapeutics, Industry Expert SaysByMary K. CaffreyJanuary 20th 2015
Best of ASH Presentations: Platelets, Lenalidomide for MDS, and Sorafenib in AMLBySurabhi Dangi-Garimella, PhDJanuary 20th 2015
Data Show High Response Rate to Ibrutinib Combination for Patients With Hard-to-Treat MCLByMary K. CaffreyJanuary 20th 2015
SPIRIT 2: Dasatinib Superior to Imatinib in Newly Diagnosed CMLBySurabhi Dangi-Garimella, PhDJanuary 19th 2015
CML Updates: Defining MMR and Results of the DASISION TrialBySurabhi Dangi-Garimella, PhDJanuary 19th 2015
Promising Results for Elotuzumab Presented in Session on Multiple MyelomaByMary K. CaffreyJanuary 19th 2015
Early Treatment, Monoclonal Antibodies Discussed in Multiple MyelomaByMary K. CaffreyJanuary 19th 2015
ASH Presents Second Round of Tests, Treatments to Question Under Choosing Wisely InitiativeByMary K. CaffreyJanuary 19th 2015
Care Plans to Reduce Healthcare Utilization in Sickle Cell DiseaseBySurabhi Dangi-Garimella, PhDJanuary 19th 2015
Healthcare Costs in Need of Solutions: Experts at ASH AgreeBySurabhi Dangi-Garimella, PhDJanuary 19th 2015
Session on Survivorship Outlines Surveillance Strategies in Non-Hodgkin LymphomaByMary K. CaffreyJanuary 19th 2015
Ibrutinib Demonstrates Significant Responses for Patients With Hard-to-Treat CLL/SLL, Phase 2 Data ShowByMary K. CaffreyJanuary 19th 2015
Study Suggests Method of Reducing Blood Clots Without Risking BleedingByMary K. CaffreyJanuary 19th 2015
